Impact of South Korea on the Pharmaceutical Industry – Thematic Intelligence
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Impact of South Korea on the Pharmaceutical Industry Report Overview
South Korea is the world’s 10th largest pharmaceutical market and considers the pharmaceutical industry a potential engine for the country’s future economic growth. South Korea is a market that offers significant potential for big pharma manufacturing, with domestic companies dominating the marketed product landscape as encouraged by government policy. Domestic pharmaceutical companies dominate the South Korean market, with the domestic industry expected to continue to grow through the encouragement provided by the South Korean government in the form of policies promoting domestic production of medicines.
The impact of South Korea on the pharmaceutical industry report provides an assessment of the major industry, regulatory, macroeconomic, and technology trends shaping the South Korea pharma industry. It provides detailed analysis of deals, clinical trials, marketed and pipeline products, and contract manufacturing. It also provides an overview of key regulatory and market access information, market drivers and barriers, and key players in the South Korean pharma sector.
Impact of South Korea on the Pharmaceutical Industry Trends
Industry Trends: The country has significant growth potential for biosimilar development. It is home to major biosimilar companies such as Celltrion, Samsung Bioepis, LG Chem, GC Green Cross, Chong Kun Dang, CJ Healthcare, and Dong-A ST. South Korean manufacturers have emerged as prominent players in the emerging market for biosimilars—not only in their home market but on an increasingly global scale. With its progressive economic growth, stable political structure, aging patient populations, and increasing governmental, private, and foreign investments, South Korea has favorable conditions to remain and expand as an advanced pharmaceutical research center. Furthermore, the increasing investments in the Healthtech is improving the country’s digital health space, further, likely to boost the pharmaceutical industry as well.
Regulatory Trends: The regulatory framework in South Korea for governing pharmaceuticals is administered by the MFDS, which replaced the Korea FDA in 2013. Drug approvals are issued by the MFDS’s central office in Osong. Since 2013, existing approvals must be reviewed and renewed every five years. New regulations and restrictive P&R policies are affecting the strategic approaches being pursued by players from both local manufacturers and foreign companies. South Korea’s government has invested heavily in the domestic biotech and biopharma sectors. Furthermore, since 2012, the sale of over-the-counter (OTC) drugs such as cold and digestive medicines, antipyretics, analgesics, and pain relief patches in stores other than a pharmacy has been legal in South Korea. Convenience stores sell around a dozen OTC drugs.
For more insight on the impact of South Korea on the pharmaceutical industry trends, download a free sample report
Impact of South Korea on the Pharmaceutical Industry Analysis
South Korean pharmaceutical market was valued at $20.6 billion in 2013 and increased to $27.9 billion in 2020 at a CAGR of 4.4%, with continued investment from the government and pharmaceutical sector. The market value is forecast to increase to $35.1 billion by 2030.
The most common deal type was strategic alliances, followed by contract service agreements (CSAs). This is in line with general deal-making trends in pharma, where there tend to be more partnerships and funding compared to CSAs.
The impact of South Korea on the pharmaceutical industry report also covers –
- Top 10 Licensing Agreements Involving South Korea by Value, 2018–22
- M&A trends
- Capital rising trends
South Korea Pharmaceutical Market Overview ($ billions), 2013–30
For more information on South Korea Pharmaceutical market forecast, download a free report sample
Impact of South Korea on the Pharmaceutical Industry by Clinical Trials
South Korea had 5,842 clinical trials identified in the region since January 2019. Oncology, CNS, and infectious disease are consistently the therapy areas with the most clinical trials. Infectious disease is the second leading therapy area in clinical trials in South Korea. In 2020, the infectious disease therapy area saw a significant increase in clinical trials, as would be expected due to the COVID-19 pandemic, with high numbers of infectious disease clinical trials continuing in 2021.
South Korea Pharmaceutical Industry Analysis by Clinical Trials, 2023 (%)
For more insights on the clinical trials in South Korea pharmaceutical industry, download a free sample report
Competitive Landscape
Domestic pharmaceutical companies dominate in South Korea, outdoing the sales and market shares of the international pharmaceutical companies located in South Korea. The key companies in the South Korean pharmaceutical industry are GSK, Celltrion, Novartis, Pfizer, Chong Kun Dang Pharmaceutical, Yuhan, Daewoong, and Samsung Biologics among others.
For more information on impact of South Korea on the pharmaceutical industry companies, download a free sample report
Impact of South Korea on the Pharmaceutical Industry Outlook
Page Count | 78 |
Key Trends | Industry Trends and Regulatory Trends |
Key Deal Types | Strategic Alliances, Mergers and Acquisitions, Contract Service Agreement, Capital Raisings |
Key Therapy Areas | Oncology, CNS, Infectious Disease, Metabolic Disorders, Respiratory, and Others |
Key Companies | GSK, Celltrion, Novartis, Pfizer, Chong Kun Dang Pharmaceutical, Yuhan, Daewoong, and Samsung Biologics |
Reasons to Buy
- See what trends are shaping the South Korean pharma market and driving innovation, including key government policies and strategic initiatives.
- Get an analysis of South Korea’s strong manufacturing and outsourcing sector, including plans to further strengthen these capabilities.
Table of Contents
Frequently asked questions
-
What are the main trends in the impact of South Korea on pharmaceutical industry?
Industry trends and regulatory trends are main trends shaping the South Korean pharmaceutical sector.
-
What are the key deal types in impact of South Korea on pharmaceutical industry?
Strategic alliances, mergers and acquisitions, contract service agreement, capital raisings are the key deal types in the South Korea on pharmaceutical industry.
-
Which are the key products in impact of South Korea on pharmaceutical industry?
Marketed products and pipeline products are the key products in impact of South Korea on pharmaceutical industry.
-
Which are the key companies in impact of South Korea on pharmaceutical industry?
GSK, Celltrion, Novartis, Pfizer, Chong Kun Dang Pharmaceutical, Yuhan, Daewoong, and Samsung Biologics are the key companies in impact of South Korea on pharmaceutical industry
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.